https://www.biopharmawatch.com/news/NTHI/neoncs-ne100-phase-2a-results-brain-cancer BiopharmaWatch en 2026-08-12T13:38:00.000Z Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer https://www.biopharmawatch.com/news/GMAB/genmab-publishes-articles-of-association BiopharmaWatch en 2026-08-12T13:32:36.000Z Genmab A/S has published its Articles of Association https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T13:30:00.000Z Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-approval-china-squamous-nsclc BiopharmaWatch en 2026-08-12T13:22:00.000Z Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/FRNM/freenome-fda-breakthrough-device-simple-screen-lung-cancer BiopharmaWatch en 2026-08-12T13:00:00.000Z FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test https://www.biopharmawatch.com/news/FEMY/femasys-global-patent-protection-fembloc BiopharmaWatch en 2026-08-12T13:00:00.000Z Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-12T13:00:00.000Z Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/CVS/cvs-caremark-employers-pharmacy-benefit-manager BiopharmaWatch en 2026-08-12T13:00:00.000Z New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions https://www.biopharmawatch.com/news/AIM/aim-immunotech-biodefense-military-force-protection BiopharmaWatch en 2026-08-12T12:44:00.000Z AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article https://www.biopharmawatch.com/news/FEED/envue-medical-secures-equity-financing-facility BiopharmaWatch en 2026-08-12T12:35:00.000Z ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-midwest-ideas-investor-conference BiopharmaWatch en 2026-08-12T12:32:00.000Z Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T12:30:00.000Z Aprea Therapeutics Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-therapy-ras-driven-cancers BiopharmaWatch en 2026-08-12T12:30:00.000Z Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers https://www.biopharmawatch.com/news/NBIX/ingrezza-kinect-pro-findings-quality-of-life BiopharmaWatch en 2026-08-12T12:30:00.000Z Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia https://www.biopharmawatch.com/news/SPRC/neurothera-japanese-patent-innovative-therapy BiopharmaWatch en 2026-08-12T12:25:00.000Z SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination https://www.biopharmawatch.com/news/VNRX/volition-rapid-point-of-care-sepsis-test BiopharmaWatch en 2026-08-12T12:17:00.000Z Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients https://www.biopharmawatch.com/news/AMIX/autonomix-medical-glp-preclinical-study-fda-submission BiopharmaWatch en 2026-08-12T12:15:00.000Z Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission https://www.biopharmawatch.com/news/SCNX/scienture-launches-rezenopy-naloxone-nasal-spray BiopharmaWatch en 2026-08-12T12:05:00.000Z SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-12T12:04:17.000Z CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-new-patents-dna-polymerase-inhibitors BiopharmaWatch en 2026-08-12T12:01:00.000Z Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics https://www.biopharmawatch.com/news/NTHI/neonc-technologies-phase-2a-results-neoi00 BiopharmaWatch en 2026-08-12T12:00:59.000Z NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma https://www.biopharmawatch.com/news/HSDT/solana-company-release-q2-2026-results BiopharmaWatch en 2026-08-12T12:00:51.000Z Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026 https://www.biopharmawatch.com/news/IPSC/century-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T12:00:44.000Z Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/AVLN/avalyn-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-12T12:00:43.000Z Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/BBLG/bone-biologics-32-month-shelf-life-rhnell-1 BiopharmaWatch en 2026-08-12T12:00:00.000Z Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1 https://www.biopharmawatch.com/news/MDGL/madrigal-appoints-john-reed-board-directors BiopharmaWatch en 2026-08-12T12:00:00.000Z Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors https://www.biopharmawatch.com/news/TVRD/tvardi-webinar-tti-109-ulcerative-colitis BiopharmaWatch en 2026-08-12T12:00:00.000Z Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 https://www.biopharmawatch.com/news/SPRB/cure-sanfilippo-foundation-investment-spruce-biosciences BiopharmaWatch en 2026-08-12T12:00:00.000Z Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences https://www.biopharmawatch.com/news/CTOR/citius-oncology-appoints-independent-director-jonathan-peri BiopharmaWatch en 2026-08-12T12:00:00.000Z Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T11:30:18.000Z Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates https://www.biopharmawatch.com/news/ADAG/adagene-financial-results-corporate-updates-2026 BiopharmaWatch en 2026-08-12T11:30:00.000Z Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q2-2026-results BiopharmaWatch en 2026-08-12T11:30:00.000Z PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALT/altimmune-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T11:30:00.000Z Altimmune Announces Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T11:19:00.000Z Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-12T11:08:00.000Z Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KMDA/kamada-record-high-financial-results-2026 BiopharmaWatch en 2026-08-12T11:05:00.000Z Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-us-patent-ath434 BiopharmaWatch en 2026-08-12T11:05:00.000Z Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 https://www.biopharmawatch.com/news/LONA/leonabio-highlight-lasofoxifene-breast-cancer-summit BiopharmaWatch en 2026-08-12T11:00:18.000Z LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-12T11:00:10.000Z Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-q2-2026-results-highlights BiopharmaWatch en 2026-08-12T11:00:10.000Z Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-12T11:00:08.000Z TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KMDA/kamada-cfo-transition-chaime-orlev BiopharmaWatch en 2026-08-12T11:00:00.000Z Kamada Announces Planned Transition of Chief Financial Officer https://www.biopharmawatch.com/news/STRO/sutro-biopharma-stro-004-phase-1-update BiopharmaWatch en 2026-08-12T11:00:00.000Z Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study https://www.biopharmawatch.com/news/HUMA/humacyte-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-12T11:00:00.000Z Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CANF/can-fite-fda-ema-regulatory-status-phase-iii-drugs BiopharmaWatch en 2026-08-12T11:00:00.000Z Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-phase-3-voyage-study-results BiopharmaWatch en 2026-08-12T11:00:00.000Z Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder https://www.biopharmawatch.com/news/UNH/unitedhealth-group-quarterly-dividend-2026 BiopharmaWatch en 2026-08-12T11:00:00.000Z UnitedHealth Group Board Authorizes Payment of Quarterly Dividend https://www.biopharmawatch.com/news/PHVS/pharvaris-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-12T10:50:07.000Z Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q2-2026-results BiopharmaWatch en 2026-08-12T10:50:00.000Z Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results https://www.biopharmawatch.com/news/BDX/bdx-prevent-trial-phasix-mesh-hernia-prevention BiopharmaWatch en 2026-08-12T10:50:00.000Z BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-q2-2026-financial-results BiopharmaWatch en 2026-08-12T10:30:00.000Z Liquidia Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TECH/bio-techne-fourth-quarter-fiscal-2026-results BiopharmaWatch en 2026-08-12T10:30:00.000Z Bio-Techne Releases Fourth Quarter Fiscal 2026 Results https://www.biopharmawatch.com/news/ANNX/annexon-reports-q2-2026-results-business-updates BiopharmaWatch en 2026-08-12T10:05:28.000Z Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones https://www.biopharmawatch.com/news/ANNX/annexon-expands-vonaprument-phase-3-program-geographic-atrophy BiopharmaWatch en 2026-08-12T10:00:32.000Z Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study https://www.biopharmawatch.com/news/NTRA/natera-support-clinical-trial-ctdna-advanced-skin-cancers BiopharmaWatch en 2026-08-12T10:00:00.000Z Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q2-2026-results BiopharmaWatch en 2026-08-12T10:00:00.000Z National Vision Holdings, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ELOX/elox-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-12T10:00:00.000Z Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LLY/lilly-fights-retatrutide-black-market BiopharmaWatch en 2026-08-12T09:30:00.000Z Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market https://www.biopharmawatch.com/news/SLBT/new-framework-developing-gamma-d-t-cell-therapy-glioblastoma BiopharmaWatch en 2026-08-12T03:49:34.000Z A New Framework for Developing γδ T Cell Therapy in Glioblastoma https://www.biopharmawatch.com/news/SLBT/t-cell-therapy-glioblastoma-framework BiopharmaWatch en 2026-08-12T03:49:19.000Z 現成型細胞治療的新可能——γδ T細胞對抗膠質母細胞瘤 https://www.biopharmawatch.com/news/SLN/silence-therapeutics-upsized-public-offering BiopharmaWatch en 2026-08-12T03:20:00.000Z Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering https://www.biopharmawatch.com/news/ALGN/align-technology-patent-victory-china BiopharmaWatch en 2026-08-12T00:47:00.000Z Align Technology Prevails in China Patent Infringement Action Against Angelalign https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-pricing-public-offering BiopharmaWatch en 2026-08-12T00:01:00.000Z Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-11T21:22:14.000Z Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-11T20:54:17.000Z Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/APLM/apollomics-announces-10-million-private-placement BiopharmaWatch en 2026-08-11T20:36:18.000Z Apollomics Announces $10 Million Private Placement Transaction https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-q2-2026-results-business-update BiopharmaWatch en 2026-08-11T20:10:27.000Z Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:10:00.000Z Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) https://www.biopharmawatch.com/news/TRLV/trulieve-redomicile-bc-to-delaware BiopharmaWatch en 2026-08-11T20:10:00.000Z Trulieve Completes Redomicile from British Columbia to Delaware https://www.biopharmawatch.com/news/VNRX/volitionrx-schedules-q2-2026-earnings-call BiopharmaWatch en 2026-08-11T20:10:00.000Z VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update https://www.biopharmawatch.com/news/ABSI/absci-reports-business-updates-q2-2026-results BiopharmaWatch en 2026-08-11T20:05:20.000Z Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-corporate-update-q2-2026 BiopharmaWatch en 2026-08-11T20:05:17.000Z Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MDAI/spectral-ai-2026-q2-financial-results BiopharmaWatch en 2026-08-11T20:05:16.000Z Spectral AI Announces 2026 Second Quarter Financial Results https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T20:05:16.000Z Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T20:05:00.000Z Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/MGNX/macrogenics-gilead-milestone-license-bispecific-program BiopharmaWatch en 2026-08-11T20:05:00.000Z MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-corporate-update-q2-2026 BiopharmaWatch en 2026-08-11T20:05:00.000Z Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 https://www.biopharmawatch.com/news/NPCE/neuropace-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance https://www.biopharmawatch.com/news/ELMD/electromed-q4-fiscal-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026 https://www.biopharmawatch.com/news/SVRA/savara-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z Savara Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/INVA/innoviva-therapies-prix-galien-finalists-2026 BiopharmaWatch en 2026-08-11T20:05:00.000Z Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-pipeline-progress-q2-2026 BiopharmaWatch en 2026-08-11T20:02:27.000Z Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMNM/immunome-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T20:02:00.000Z Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:01:32.000Z Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q2-2026-update BiopharmaWatch en 2026-08-11T20:01:30.000Z Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BLTE/belite-bio-fda-acceptance-tinlarebant-stargardt-disease BiopharmaWatch en 2026-08-11T20:01:28.000Z Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/STXS/stxs-second-quarter-financial-results-2026 BiopharmaWatch en 2026-08-11T20:01:00.000Z Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:01:00.000Z Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity https://www.biopharmawatch.com/news/ERAS/erasca-reports-q2-2026-business-updates BiopharmaWatch en 2026-08-11T20:01:00.000Z Erasca Reports Second Quarter 2026 Business Updates and Financial Results https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q2-2026-results-update BiopharmaWatch en 2026-08-11T20:00:28.000Z Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:00:00.000Z TherapeuticsMD Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:00:00.000Z AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights https://www.biopharmawatch.com/news/ACB/aurora-cannabis-responds-curaleaf-takeover-bid BiopharmaWatch en 2026-08-11T19:22:00.000Z AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID https://www.biopharmawatch.com/news/GMAB/genmab-capital-increase-employee-warrant-exercise BiopharmaWatch en 2026-08-11T17:54:09.000Z Capital Increase in Genmab as a Result of Employee Warrant Exercise https://www.biopharmawatch.com/news/CRDL/inflammation-heart-why-field-asking-different-question BiopharmaWatch en 2026-08-11T14:19:51.000Z Inflammation and the Heart: Why the Field Is Asking a Different Question https://www.biopharmawatch.com/news/VOR/vor-bio-reports-q2-2026-results BiopharmaWatch en 2026-08-11T13:30:10.000Z Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IGC/igc-pharma-strengthens-regulatory-readiness-calma-trial BiopharmaWatch en 2026-08-11T13:17:13.000Z IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout https://www.biopharmawatch.com/news/AVXL/anavex-highlights-board-actions-long-term-value BiopharmaWatch en 2026-08-11T12:42:53.000Z Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders https://www.biopharmawatch.com/news/RNXT/renovorx-phase-iii-tiger-pac-trial-enrollment-complete BiopharmaWatch en 2026-08-11T12:30:00.000Z RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-11T12:30:00.000Z Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-q2-2026-results BiopharmaWatch en 2026-08-11T12:30:00.000Z Adagio Medical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/WGS/genedx-online-offering-exome-testing-children BiopharmaWatch en 2026-08-11T12:30:00.000Z GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-fibroblasts-islet-transplantation BiopharmaWatch en 2026-08-11T12:30:00.000Z FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets https://www.biopharmawatch.com/news/ACB/curaleaf-takeover-bid-aurora-cannabis BiopharmaWatch en 2026-08-11T12:25:00.000Z Curaleaf Announces Intention to Launch Take-Over Bid for Aurora Cannabis to Solidify its Position as the Global Cannabis Industry Leader https://www.biopharmawatch.com/news/RKTO/rocket-one-seagate-partner-program-ai-infrastructure BiopharmaWatch en 2026-08-11T12:12:00.000Z Rocket One Accepted into Seagate Partner Program, Expanding AI Infrastructure and Enterprise Data Storage Ecosystem https://www.biopharmawatch.com/news/BFLY/butterfly-network-congratulates-dr-erica-schwartz-cdc-director BiopharmaWatch en 2026-08-11T12:05:00.000Z Butterfly Network Congratulates Dr. Erica Schwartz on Confirmation as CDC Director https://www.biopharmawatch.com/news/KLRS/kalaris-q2-2026-financial-results-business-updates BiopharmaWatch en 2026-08-11T12:00:35.000Z Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-11T12:00:00.000Z Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-imcivree-authorization-uk BiopharmaWatch en 2026-08-11T12:00:00.000Z Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment https://www.biopharmawatch.com/news/IMNN/imunon-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-11T12:00:00.000Z IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-activates-fourth-clinical-site BiopharmaWatch en 2026-08-11T12:00:00.000Z Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/ARDT/oklahoma-heart-institute-national-cardiovascular-trials BiopharmaWatch en 2026-08-11T12:00:00.000Z Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region https://www.biopharmawatch.com/news/COYA/coya-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T12:00:00.000Z Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/HSTM/humana-health-horizons-healthstream-home-care-workforce BiopharmaWatch en 2026-08-11T12:00:00.000Z Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce https://www.biopharmawatch.com/news/NVO/novonordisk-launches-awiqli-weekly-basal-insulin BiopharmaWatch en 2026-08-11T12:00:00.000Z Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US https://www.biopharmawatch.com/news/MREO/sentynl-mereo-alvelestat-agreement-aatd-lung-disease BiopharmaWatch en 2026-08-11T12:00:00.000Z Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-teluride-006-dose-selection BiopharmaWatch en 2026-08-11T11:30:36.000Z Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-leadership-transition-growth BiopharmaWatch en 2026-08-11T11:30:28.000Z Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:30:00.000Z Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/MANE/veradermics-q2-2026-financial-results-clinical-progress BiopharmaWatch en 2026-08-11T11:30:00.000Z Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/NGNE/neurogene-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-11T11:30:00.000Z Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates https://www.biopharmawatch.com/news/OGN/organon-rems-program-miu-della-launch BiopharmaWatch en 2026-08-11T11:30:00.000Z Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability https://www.biopharmawatch.com/news/ZURA/zura-bio-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:30:00.000Z Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T11:30:00.000Z Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LLY/eli-lilly-veeva-vault-crm-global-implementation BiopharmaWatch en 2026-08-11T11:03:00.000Z Veeva Vault CRM seleccionado por Eli Lilly and Company https://www.biopharmawatch.com/news/LLY/veeva-vault-crm-selected-by-eli-lilly BiopharmaWatch en 2026-08-11T11:03:00.000Z Veeva Vault CRM Selected by Eli Lilly and Company https://www.biopharmawatch.com/news/LLY/eli-lilly-selects-veeva-vault-crm BiopharmaWatch en 2026-08-11T11:03:00.000Z Veeva Vault CRM von Eli Lilly and Company ausgewählt https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-us-notice-allowance-ph-894 BiopharmaWatch en 2026-08-11T11:01:11.000Z Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:01:00.000Z Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/UPB/upstream-bio-q2-2026-financial-results-progress BiopharmaWatch en 2026-08-11T11:00:44.000Z Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-11T11:00:42.000Z C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-11T11:00:42.000Z Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-appoints-nur-nicholson-cto BiopharmaWatch en 2026-08-11T11:00:35.000Z Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-phase-1-study-prt13722 BiopharmaWatch en 2026-08-11T11:00:30.000Z Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-11T11:00:29.000Z Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/CALC/calcimedica-reports-q2-2026-results BiopharmaWatch en 2026-08-11T11:00:00.000Z CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates https://www.biopharmawatch.com/news/LEGN/legend-biotech-q2-2026-results-highlights BiopharmaWatch en 2026-08-11T11:00:00.000Z Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights https://www.biopharmawatch.com/news/ACIU/fda-fast-track-aciu-aci-7104-parkinsons BiopharmaWatch en 2026-08-11T11:00:00.000Z AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) https://www.biopharmawatch.com/news/AURA/aura-biosciences-phase-3-trial-enrollment-update BiopharmaWatch en 2026-08-11T11:00:00.000Z Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/BRKR/bruker-collaboration-atinary-technologies BiopharmaWatch en 2026-08-11T11:00:00.000Z Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories https://www.biopharmawatch.com/news/KARD/kardigan-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:00:00.000Z Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:00:00.000Z Xtant Medical Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CAH/cardinal-health-fiscal-year-2026-results-guidance BiopharmaWatch en 2026-08-11T10:45:00.000Z Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-q2-2026-results BiopharmaWatch en 2026-08-11T10:30:00.000Z DarioHealth Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMUX/immunic-reports-q2-2026-results-and-update BiopharmaWatch en 2026-08-11T10:30:00.000Z Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/YDES/yd-bio-launches-new-healthcare-models-taiwan BiopharmaWatch en 2026-08-11T09:22:27.000Z YD Bio 在台灣啟動醫師夥伴計畫，推出兩款時間營養學配方 https://www.biopharmawatch.com/news/YDES/yd-bio-physician-partnership-taiwan-chrono-nutrition BiopharmaWatch en 2026-08-11T09:22:22.000Z YD Bio Launches a Physician-Partnership Initiative in Taiwan with Two Chrono-Nutrition Formulations https://www.biopharmawatch.com/news/RVMD/beone-revolution-medicines-partnership-oncology BiopharmaWatch en 2026-08-10T21:07:00.000Z BeOne Medicines وRevolution Medicines تعلنان عن شراكة للتطوير السريري والتسويق التجاري الإقليمي https://www.biopharmawatch.com/news/KOD/kodiak-sciences-phase-3-alto-trial-ksi-501 BiopharmaWatch en 2026-08-10T20:43:00.000Z Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema https://www.biopharmawatch.com/news/SCYX/scynexis-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T20:30:00.000Z SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-10T20:30:00.000Z DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/ALC/alcon-second-quarter-2026-growth BiopharmaWatch en 2026-08-10T20:30:00.000Z New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth https://www.biopharmawatch.com/news/EHC/encompass-health-prices-additional-senior-notes-offering BiopharmaWatch en 2026-08-10T20:30:00.000Z Encompass Health prices private offering of additional 5.875% senior notes due 2034 https://www.biopharmawatch.com/news/JNJ/johnson-johnson-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-08-10T20:27:00.000Z Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q2-2026-results-highlights BiopharmaWatch en 2026-08-10T20:24:37.000Z Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-q2-2026-results-phase-2-development BiopharmaWatch en 2026-08-10T20:20:15.000Z Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development https://www.biopharmawatch.com/news/AGMB/agomab-proposed-appointments-board-directors BiopharmaWatch en 2026-08-10T20:07:49.000Z Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors https://www.biopharmawatch.com/news/ALMS/envudeucitinib-long-term-data-plaque-psoriasis-treatment BiopharmaWatch en 2026-08-10T20:05:37.000Z Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies https://www.biopharmawatch.com/news/PROK/prokidney-reports-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:36.000Z ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-business-updates-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:36.000Z Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANNX/annexon-appoints-mark-blumenkranz-board-directors BiopharmaWatch en 2026-08-10T20:05:36.000Z Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:30.000Z Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HROW/harrow-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-10T20:05:30.000Z Harrow Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q2-2026-results-updates BiopharmaWatch en 2026-08-10T20:05:22.000Z Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/CBLL/ceribell-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-10T20:05:00.000Z Ceribell Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:00.000Z Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-bloodstream-infection-panel BiopharmaWatch en 2026-08-10T20:05:00.000Z QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel https://www.biopharmawatch.com/news/HIMS/hims-hers-health-q2-2026-financial-results BiopharmaWatch en 2026-08-10T20:05:00.000Z Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PIII/p3-health-partners-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:00.000Z P3 Health Partners Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/IMUX/immunic-appoints-elena-ridloff-board-directors BiopharmaWatch en 2026-08-10T20:05:00.000Z Immunic Appoints Elena Ridloff to Board of Directors https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-q2-2026-results BiopharmaWatch en 2026-08-10T20:02:00.000Z Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-q2-2026-results BiopharmaWatch en 2026-08-10T20:01:49.000Z Olema Oncology Reports Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/SEPN/septerna-business-progress-q2-2026-results BiopharmaWatch en 2026-08-10T20:01:36.000Z Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ERAS/erasca-inducement-grants-nasdaq-listing-rule-5635c4 BiopharmaWatch en 2026-08-10T20:01:00.000Z Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-financial-results-q3-2026 BiopharmaWatch en 2026-08-10T20:01:00.000Z Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/SLN/silence-therapeutics-public-offering-150-million BiopharmaWatch en 2026-08-10T20:01:00.000Z Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-10T20:00:00.000Z Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress